You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfamethoxazole
Accession NumberDB01015  (APRD00076)
TypeSmall Molecule
GroupsApproved
DescriptionA bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
Structure
Thumb
Synonyms
3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
Gantanol (tn)
SMX
Sulfamethoxazole
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sulfamethoxazole Tab 500mgtablet500 mgoralPro Doc Limitee1978-12-311999-08-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfamethoxazole Tab 500mgtablet500 mgoralApotex Inc1978-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GantanolNot Available
SinominNot Available
UrobakNot Available
Brand mixtures
NameLabellerIngredients
Apo Sulfatrim DS TabApotex Inc
Apo Sulfatrim PediatricApotex Inc
Apo Sulfatrim TabApotex Inc
Apo-sulfatrim Oral SuspensionApotex Inc
BactrimAR Scientific, Inc.
Bactrim DSAR Scientific, Inc.
Bactrim DS Roche TabHoffmann La Roche Limited
Bactrim Roche InjHoffmann La Roche Limited
Bactrim Roche Suspension PaediatricHoffmann La Roche Limited
Bactrim Roche TabHoffmann La Roche Limited
Nu-cotrimox Sus 40/8mg/mlNu Pharm Inc
Nu-cotrimox Tab 400/80mgNu Pharm Inc
Nu-cotrimox-DS Tab 800/160mgNu Pharm Inc
Protrin Df TabPro Doc Limitee
Protrin TabPro Doc Limitee
Riva-sep DSLaboratoire Riva Inc
Roubac Tab 160/800Rougier Pharma Division Of Ratiopharm Inc
Roubac Tab 80/400Rougier Pharma Division Of Ratiopharm Inc
SeptraGlaxosmithkline Inc
Septra DS TabletsGlaxosmithkline Inc
Septra InjectionAspen Pharma Trading Limited
Septra Pediatric SuspensionGlaxosmithkline Inc
Sulfamethoxazole and TrimethoprimTeva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim (double Strength)Teva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim Double StrengthLake Erie Medical Dba Quality L Care Products Lc
Sulfamethoxazole and Trimethoprim DSApotheca Inc.
Sulfamethoxazole and Trimethoprim TabletsD.C. Labs Limited
SulfatrimSTI Pharma LLC
Teva-trimelTeva Canada Limited
Teva-trimel DSTeva Canada Limited
Trisulfa DS TabJaapharm Canada Inc.
Trisulfa S SuspensionJaapharm Canada Inc.
Trisulfa TabJaapharm Canada Inc.
SaltsNot Available
Categories
UNIIJE42381TNV
CAS number723-46-6
WeightAverage: 253.278
Monoisotopic: 253.052111923
Chemical FormulaC10H11N3O3S
InChI KeyInChIKey=JLKIGFTWXXRPMT-UHFFFAOYSA-N
InChI
InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
IUPAC Name
4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
SMILES
CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Aminobenzenesulfonamide
  • Sulfonylaniline
  • Substituted aniline
  • Aniline
  • Imidolactam
  • Primary aromatic amine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxazole
  • Isoxazole
  • Azole
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections.
PharmacodynamicsSulfamethoxazole is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethoxazole is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA. Sulfamethoxazole is normally given in combination with Trimethoprim, a dihydrofolate reductase inhibitor, which inhibits the reduction of dihydrofolic acid to tetrahydrofolic acid. Studies have shown that bacterial resistance develops more slowly with the combination of the two drugs than with either Trimethoprim or Sulfamethoxazole alone.
Mechanism of actionSulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.
Related Articles
AbsorptionRapidly absorbed following oral administration. Also well-absorbed topically.
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic. The metabolism of sulfamethoxazole occurs predominately by N4-acetylation, although the glucuronide conjugate has been identified.

SubstrateEnzymesProduct
Sulfamethoxazole
5-HydroxysulfamethoxazoleDetails
Sulfamethoxazole
N4-AcetylsulfamethoxazoleDetails
Sulfamethoxazole
Not Available
Sulfamethoxazole N1-glucuronideDetails
Sulfamethoxazole
Sulfamethoxazole N4-hydroxylamineDetails
5-Hydroxysulfamethoxazole
N4-Acetyl-5-OH-sulfamethoxazoleDetails
N4-Acetylsulfamethoxazole
Not Available
N4-Acetyl-5-OH-sulfamethoxazoleDetails
Sulfamethoxazole N4-hydroxylamine
Not Available
Nitroso-sulfamethoxazoleDetails
Nitroso-sulfamethoxazole
Not Available
Sulfamethoxazole GSH conjugateDetails
Route of eliminationNot Available
Half life10 hours
ClearanceNot Available
ToxicitySulfamethoxazole may cause nausea, vomiting, diarrhea and hypersensitivity reactions. Hematologic effects such as anemia, agranulocytosis, thrombocytopenia and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency may also occur. Sulfamethoxazole may displace bilirubin from albumin binding sites causing jaundice or kernicterus in newborns.
Affected organisms
  • Gram negative and gram positive bacteria
  • Listeria monocytogenes
  • Escherichia coli
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5346
P-glycoprotein substrateNon-substrate0.8884
P-glycoprotein inhibitor INon-inhibitor0.9362
P-glycoprotein inhibitor IINon-inhibitor0.8754
Renal organic cation transporterNon-inhibitor0.9195
CYP450 2C9 substrateNon-substrate0.7652
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7632
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7151
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8193
BiodegradationNot ready biodegradable0.9882
Rat acute toxicity1.6422 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9143
hERG inhibition (predictor II)Non-inhibitor0.8956
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • Heather drug co inc
  • Sandoz inc
  • Watson laboratories inc
  • Shionogi usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
Liquidintravenous
Solutionintravenous
Injection, solution, concentrateintravenous
Suspensionoral
Tabletoral
Prices
Unit descriptionCostUnit
Sulfamethoxazole-TMP DS 800-160 mg tablet0.94USD tablet
Sulfamethoxazole powder0.41USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point167 °CPhysProp
water solubility610 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.89HANSCH,C ET AL. (1995)
logS-2.62ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.459 mg/mLALOGPS
logP0.79ALOGPS
logP0.79ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)6.16ChemAxon
pKa (Strongest Basic)1.97ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.5 m3·mol-1ChemAxon
Polarizability24.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.61 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yasushi Takagishi, Kiichiro Ohsuga, Sadao Ohama, “Suppository containing sulfamethoxazole/trimethoprim complex and process for preparing the same.” U.S. Patent US4461765, issued December, 1975.

US4461765
General ReferencesNot Available
External Links
ATC CodesJ01EC01J01EE01
AHFS Codes
  • 08:12.20
PDB Entries
FDA labelNot Available
MSDSDownload (35 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Sulfamethoxazole.
AbirateroneThe metabolism of Sulfamethoxazole can be decreased when combined with Abiraterone.
AcarboseAcarbose may increase the hypoglycemic activities of Sulfamethoxazole.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sulfamethoxazole.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sulfamethoxazole.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sulfamethoxazole.
AcetohexamideSulfamethoxazole may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfamethoxazole.
AicarAicar may increase the hypoglycemic activities of Sulfamethoxazole.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sulfamethoxazole.
AlogliptinAlogliptin may increase the hypoglycemic activities of Sulfamethoxazole.
AlosetronThe metabolism of Alosetron can be decreased when combined with Sulfamethoxazole.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sulfamethoxazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sulfamethoxazole.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Sulfamethoxazole.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Sulfamethoxazole.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sulfamethoxazole.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Sulfamethoxazole.
AmoxapineAmoxapine may increase the hypoglycemic activities of Sulfamethoxazole.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sulfamethoxazole.
AnagrelideSulfamethoxazole may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sulfamethoxazole.
ApixabanThe metabolism of Apixaban can be decreased when combined with Sulfamethoxazole.
AprepitantThe serum concentration of Sulfamethoxazole can be increased when it is combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sulfamethoxazole.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sulfamethoxazole.
Arsenic trioxideSulfamethoxazole may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Artemether can be decreased when combined with Sulfamethoxazole.
AsenapineSulfamethoxazole may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Sulfamethoxazole can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Sulfamethoxazole can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Sulfamethoxazole.
AzathioprineSulfamethoxazole may increase the myelosuppressive activities of Azathioprine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Sulfamethoxazole.
AzithromycinSulfamethoxazole may increase the QTc-prolonging activities of Azithromycin.
BedaquilineSulfamethoxazole may increase the QTc-prolonging activities of Bedaquiline.
BenmoxinBenmoxin may increase the hypoglycemic activities of Sulfamethoxazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sulfamethoxazole.
BeraprostThe metabolism of Beraprost can be decreased when combined with Sulfamethoxazole.
BexaroteneThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sulfamethoxazole.
BoceprevirThe metabolism of Sulfamethoxazole can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Sulfamethoxazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sulfamethoxazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sulfamethoxazole.
BuforminBuformin may increase the hypoglycemic activities of Sulfamethoxazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sulfamethoxazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Sulfamethoxazole.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Sulfamethoxazole.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sulfamethoxazole.
CaffeineThe metabolism of Caffeine can be decreased when combined with Sulfamethoxazole.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
CandesartanThe metabolism of Candesartan can be decreased when combined with Sulfamethoxazole.
CapecitabineThe metabolism of Sulfamethoxazole can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Sulfamethoxazole can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sulfamethoxazole.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Sulfamethoxazole.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sulfamethoxazole.
CastanospermineCastanospermine may increase the hypoglycemic activities of Sulfamethoxazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sulfamethoxazole.
CeritinibThe serum concentration of Sulfamethoxazole can be increased when it is combined with Ceritinib.
CeritinibSulfamethoxazole may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Sulfamethoxazole.
ChloroquineSulfamethoxazole may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineSulfamethoxazole may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideSulfamethoxazole may increase the hypoglycemic activities of Chlorpropamide.
CholecalciferolThe metabolism of Sulfamethoxazole can be decreased when combined with Cholecalciferol.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Sulfamethoxazole.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sulfamethoxazole.
CiprofloxacinSulfamethoxazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Sulfamethoxazole.
CitalopramCitalopram may increase the hypoglycemic activities of Sulfamethoxazole.
CitalopramSulfamethoxazole may increase the QTc-prolonging activities of Citalopram.
ClarithromycinSulfamethoxazole may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Sulfamethoxazole can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Sulfamethoxazole can be decreased when combined with Clemastine.
ClomipramineClomipramine may increase the hypoglycemic activities of Sulfamethoxazole.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sulfamethoxazole.
ClotrimazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Clotrimazole.
ClozapineSulfamethoxazole may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Sulfamethoxazole can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Sulfamethoxazole can be increased when it is combined with Conivaptan.
CrizotinibSulfamethoxazole may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Sulfamethoxazole can be decreased when combined with Crizotinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sulfamethoxazole.
CyclosporineSulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Sulfamethoxazole can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Sulfamethoxazole.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sulfamethoxazole.
DapoxetineDapoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Sulfamethoxazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Sulfamethoxazole.
DarunavirThe metabolism of Sulfamethoxazole can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sulfamethoxazole.
DasatinibThe serum concentration of Sulfamethoxazole can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Sulfamethoxazole can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethoxazole.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sulfamethoxazole.
DiazepamThe metabolism of Diazepam can be decreased when combined with Sulfamethoxazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sulfamethoxazole.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sulfamethoxazole.
DiflunisalDiflunisal may increase the hypoglycemic activities of Sulfamethoxazole.
DihydroergotamineThe metabolism of Sulfamethoxazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Sulfamethoxazole.
DiltiazemThe metabolism of Sulfamethoxazole can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sulfamethoxazole.
DisopyramideDisopyramide may increase the hypoglycemic activities of Sulfamethoxazole.
DofetilideSulfamethoxazole may increase the QTc-prolonging activities of Dofetilide.
DolasetronSulfamethoxazole may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Sulfamethoxazole.
DonepezilThe metabolism of Donepezil can be decreased when combined with Sulfamethoxazole.
DopamineThe metabolism of Dopamine can be decreased when combined with Sulfamethoxazole.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Sulfamethoxazole.
DoxepinThe metabolism of Doxepin can be decreased when combined with Sulfamethoxazole.
DoxycyclineThe metabolism of Sulfamethoxazole can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sulfamethoxazole.
DronedaroneThe metabolism of Sulfamethoxazole can be decreased when combined with Dronedarone.
DronedaroneSulfamethoxazole may increase the QTc-prolonging activities of Dronedarone.
DroperidolSulfamethoxazole may increase the QTc-prolonging activities of Droperidol.
DulaglutideDulaglutide may increase the hypoglycemic activities of Sulfamethoxazole.
EfavirenzThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Sulfamethoxazole.
EliglustatSulfamethoxazole may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Sulfamethoxazole.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
EnzalutamideThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Sulfamethoxazole.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Sulfamethoxazole.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole.
ErythromycinSulfamethoxazole may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Sulfamethoxazole can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Sulfamethoxazole.
EscitalopramSulfamethoxazole may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe metabolism of Estradiol can be decreased when combined with Sulfamethoxazole.
EstroneThe metabolism of Estrone can be decreased when combined with Sulfamethoxazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sulfamethoxazole.
Ethyl biscoumacetateSulfamethoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacThe metabolism of Etodolac can be decreased when combined with Sulfamethoxazole.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Sulfamethoxazole.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.
EtravirineThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Sulfamethoxazole.
ExenatideExenatide may increase the hypoglycemic activities of Sulfamethoxazole.
FenfluramineFenfluramine may increase the hypoglycemic activities of Sulfamethoxazole.
FlecainideSulfamethoxazole may increase the QTc-prolonging activities of Flecainide.
FloxuridineThe metabolism of Sulfamethoxazole can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sulfamethoxazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sulfamethoxazole.
FluorouracilThe metabolism of Sulfamethoxazole can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Sulfamethoxazole.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Sulfamethoxazole.
FlupentixolSulfamethoxazole may increase the QTc-prolonging activities of Flupentixol.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sulfamethoxazole.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sulfamethoxazole.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Sulfamethoxazole.
FormoterolThe metabolism of Formoterol can be decreased when combined with Sulfamethoxazole.
FosamprenavirThe metabolism of Sulfamethoxazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sulfamethoxazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Sulfamethoxazole can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Sulfamethoxazole.
Fusidic AcidThe serum concentration of Sulfamethoxazole can be increased when it is combined with Fusidic Acid.
Gadobenic acidSulfamethoxazole may increase the QTc-prolonging activities of Gadobenic acid.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sulfamethoxazole.
GemfibrozilThe metabolism of Sulfamethoxazole can be decreased when combined with Gemfibrozil.
GemifloxacinSulfamethoxazole may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideSulfamethoxazole may increase the hypoglycemic activities of Glibornuride.
GliclazideSulfamethoxazole may increase the hypoglycemic activities of Gliclazide.
GlimepirideSulfamethoxazole may increase the hypoglycemic activities of Glimepiride.
GlipizideSulfamethoxazole may increase the hypoglycemic activities of Glipizide.
GliquidoneSulfamethoxazole may increase the hypoglycemic activities of Gliquidone.
GlisoxepideSulfamethoxazole may increase the hypoglycemic activities of Glisoxepide.
GlyburideSulfamethoxazole may increase the hypoglycemic activities of Glyburide.
GoserelinSulfamethoxazole may increase the QTc-prolonging activities of Goserelin.
GranisetronSulfamethoxazole may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sulfamethoxazole.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Sulfamethoxazole.
HaloperidolSulfamethoxazole may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Sulfamethoxazole.
HexamethylenetetramineThe risk or severity of adverse effects can be increased when Hexamethylenetetramine is combined with Sulfamethoxazole.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sulfamethoxazole.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Sulfamethoxazole.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Sulfamethoxazole.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sulfamethoxazole.
IbutilideSulfamethoxazole may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sulfamethoxazole.
IdelalisibThe serum concentration of Sulfamethoxazole can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sulfamethoxazole.
IloperidoneSulfamethoxazole may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Sulfamethoxazole can be decreased when combined with Imatinib.
IndalpineIndalpine may increase the hypoglycemic activities of Sulfamethoxazole.
IndinavirThe metabolism of Sulfamethoxazole can be decreased when combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Sulfamethoxazole.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sulfamethoxazole.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin HumanInsulin Human may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Sulfamethoxazole.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Sulfamethoxazole.
IproclozideIproclozide may increase the hypoglycemic activities of Sulfamethoxazole.
IproniazidIproniazid may increase the hypoglycemic activities of Sulfamethoxazole.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.
IsavuconazoniumThe metabolism of Sulfamethoxazole can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Sulfamethoxazole.
IsradipineThe metabolism of Sulfamethoxazole can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Sulfamethoxazole can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sulfamethoxazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Sulfamethoxazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sulfamethoxazole.
KetoconazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole.
LanreotideSulfamethoxazole may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sulfamethoxazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sulfamethoxazole.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Sulfamethoxazole.
LenvatinibSulfamethoxazole may increase the QTc-prolonging activities of Lenvatinib.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sulfamethoxazole.
LeuprolideSulfamethoxazole may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinSulfamethoxazole may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Sulfamethoxazole.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Sulfamethoxazole.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sulfamethoxazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sulfamethoxazole.
LinagliptinLinagliptin may increase the hypoglycemic activities of Sulfamethoxazole.
LiraglutideLiraglutide may increase the hypoglycemic activities of Sulfamethoxazole.
LoperamideThe metabolism of Loperamide can be decreased when combined with Sulfamethoxazole.
LopinavirThe metabolism of Sulfamethoxazole can be decreased when combined with Lopinavir.
LopinavirSulfamethoxazole may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Sulfamethoxazole.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.
LosartanThe metabolism of Sulfamethoxazole can be decreased when combined with Losartan.
LovastatinThe metabolism of Sulfamethoxazole can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Sulfamethoxazole.
LuliconazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Lumacaftor.
LumefantrineSulfamethoxazole may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sulfamethoxazole.
MebanazineMebanazine may increase the hypoglycemic activities of Sulfamethoxazole.
MecamylamineThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.
MecaserminSulfamethoxazole may increase the hypoglycemic activities of Mecasermin.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sulfamethoxazole.
MelatoninThe metabolism of Melatonin can be decreased when combined with Sulfamethoxazole.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sulfamethoxazole.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sulfamethoxazole.
MercaptopurineSulfamethoxazole may increase the myelosuppressive activities of Mercaptopurine.
MesalazineMesalazine may increase the hypoglycemic activities of Sulfamethoxazole.
MestranolThe metabolism of Mestranol can be decreased when combined with Sulfamethoxazole.
MetforminMetformin may increase the hypoglycemic activities of Sulfamethoxazole.
MethadoneSulfamethoxazole may increase the QTc-prolonging activities of Methadone.
MethotrexateThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Methotrexate.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sulfamethoxazole.
Methylene blueMethylene blue may increase the hypoglycemic activities of Sulfamethoxazole.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Sulfamethoxazole.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sulfamethoxazole.
MifepristoneMifepristone may increase the hypoglycemic activities of Sulfamethoxazole.
MiglitolMiglitol may increase the hypoglycemic activities of Sulfamethoxazole.
MiglustatMiglustat may increase the hypoglycemic activities of Sulfamethoxazole.
MilnacipranMilnacipran may increase the hypoglycemic activities of Sulfamethoxazole.
MinaprineMinaprine may increase the hypoglycemic activities of Sulfamethoxazole.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sulfamethoxazole.
MitiglinideMitiglinide may increase the hypoglycemic activities of Sulfamethoxazole.
MitotaneThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypoglycemic activities of Sulfamethoxazole.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sulfamethoxazole.
ModafinilThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Modafinil.
MontelukastThe metabolism of Montelukast can be decreased when combined with Sulfamethoxazole.
MorphineThe metabolism of Morphine can be decreased when combined with Sulfamethoxazole.
MoxifloxacinSulfamethoxazole may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Sulfamethoxazole.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfamethoxazole.
NafcillinThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Nafcillin.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Sulfamethoxazole.
NaproxenThe metabolism of Naproxen can be decreased when combined with Sulfamethoxazole.
NateglinideNateglinide may increase the hypoglycemic activities of Sulfamethoxazole.
NefazodoneThe metabolism of Sulfamethoxazole can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Sulfamethoxazole can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Sulfamethoxazole can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Sulfamethoxazole.
NevirapineThe metabolism of Sulfamethoxazole can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypoglycemic activities of Sulfamethoxazole.
NicardipineThe metabolism of Sulfamethoxazole can be decreased when combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sulfamethoxazole.
NicotineThe metabolism of Nicotine can be decreased when combined with Sulfamethoxazole.
NilotinibThe metabolism of Sulfamethoxazole can be decreased when combined with Nilotinib.
NilotinibSulfamethoxazole may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sulfamethoxazole.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sulfamethoxazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sulfamethoxazole.
OctamoxinOctamoxin may increase the hypoglycemic activities of Sulfamethoxazole.
OctreotideOctreotide may increase the hypoglycemic activities of Sulfamethoxazole.
OfloxacinSulfamethoxazole may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Sulfamethoxazole.
OlaparibThe metabolism of Sulfamethoxazole can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sulfamethoxazole.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Sulfamethoxazole.
OmeprazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Omeprazole.
OndansetronSulfamethoxazole may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Sulfamethoxazole can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sulfamethoxazole.
OxandroloneOxandrolone may increase the hypoglycemic activities of Sulfamethoxazole.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sulfamethoxazole.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Sulfamethoxazole.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Sulfamethoxazole.
PalbociclibThe serum concentration of Sulfamethoxazole can be increased when it is combined with Palbociclib.
PaliperidoneSulfamethoxazole may increase the QTc-prolonging activities of Paliperidone.
PanobinostatSulfamethoxazole may increase the QTc-prolonging activities of Panobinostat.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sulfamethoxazole.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Sulfamethoxazole.
PargylinePargyline may increase the hypoglycemic activities of Sulfamethoxazole.
ParoxetineParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
PasireotideSulfamethoxazole may increase the hypoglycemic activities of Pasireotide.
PazopanibSulfamethoxazole may increase the QTc-prolonging activities of Pazopanib.
PegvisomantPegvisomant may increase the hypoglycemic activities of Sulfamethoxazole.
PentamidineSulfamethoxazole may increase the QTc-prolonging activities of Pentamidine.
PentamidinePentamidine may increase the hypoglycemic activities of Sulfamethoxazole.
PentobarbitalThe metabolism of Sulfamethoxazole can be increased when combined with Pentobarbital.
PerflutrenSulfamethoxazole may increase the QTc-prolonging activities of Perflutren.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sulfamethoxazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sulfamethoxazole.
PhenelzinePhenelzine may increase the hypoglycemic activities of Sulfamethoxazole.
PhenforminPhenformin may increase the hypoglycemic activities of Sulfamethoxazole.
PhenindioneSulfamethoxazole may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Sulfamethoxazole.
PhenobarbitalThe metabolism of Sulfamethoxazole can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Sulfamethoxazole.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sulfamethoxazole.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sulfamethoxazole.
PhenytoinThe metabolism of Sulfamethoxazole can be increased when combined with Phenytoin.
PimozideSulfamethoxazole may increase the QTc-prolonging activities of Pimozide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Sulfamethoxazole.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sulfamethoxazole.
PirlindolePirlindole may increase the hypoglycemic activities of Sulfamethoxazole.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sulfamethoxazole.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Sulfamethoxazole.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Sulfamethoxazole.
PosaconazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Posaconazole.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Sulfamethoxazole.
PramlintidePramlintide may increase the hypoglycemic activities of Sulfamethoxazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sulfamethoxazole.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sulfamethoxazole.
PrilocaineThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Prilocaine.
PrimaquineSulfamethoxazole may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Sulfamethoxazole can be increased when combined with Primidone.
ProcainamideSulfamethoxazole may increase the QTc-prolonging activities of Procainamide.
ProcaineThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Procaine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sulfamethoxazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Sulfamethoxazole.
PromazineSulfamethoxazole may increase the QTc-prolonging activities of Promazine.
PropafenoneSulfamethoxazole may increase the QTc-prolonging activities of Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Sulfamethoxazole.
PyrimethamineThe metabolism of Sulfamethoxazole can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Sulfamethoxazole.
QuetiapineSulfamethoxazole may increase the QTc-prolonging activities of Quetiapine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Sulfamethoxazole.
QuinineQuinine may increase the hypoglycemic activities of Sulfamethoxazole.
RanolazineThe metabolism of Sulfamethoxazole can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypoglycemic activities of Sulfamethoxazole.
RepaglinideRepaglinide may increase the hypoglycemic activities of Sulfamethoxazole.
RifabutinThe metabolism of Sulfamethoxazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Sulfamethoxazole can be increased when combined with Rifampicin.
RifapentineThe metabolism of Sulfamethoxazole can be increased when combined with Rifapentine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Sulfamethoxazole.
RitonavirThe metabolism of Sulfamethoxazole can be decreased when combined with Ritonavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sulfamethoxazole.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Sulfamethoxazole.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sulfamethoxazole.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sulfamethoxazole.
SafrazineSafrazine may increase the hypoglycemic activities of Sulfamethoxazole.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sulfamethoxazole.
SaquinavirSulfamethoxazole may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Sulfamethoxazole can be decreased when combined with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Sulfamethoxazole.
SecobarbitalThe metabolism of Sulfamethoxazole can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Sulfamethoxazole.
SelegilineThe metabolism of Selegiline can be decreased when combined with Sulfamethoxazole.
SelexipagThe metabolism of Selexipag can be decreased when combined with Sulfamethoxazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sulfamethoxazole.
SertralineSertraline may increase the hypoglycemic activities of Sulfamethoxazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Sulfamethoxazole.
SildenafilThe metabolism of Sulfamethoxazole can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sulfamethoxazole can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sulfamethoxazole.
SitagliptinSitagliptin may increase the hypoglycemic activities of Sulfamethoxazole.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Sulfamethoxazole.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Sulfamethoxazole.
Sodium NitriteThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Sodium Nitrite.
SorafenibThe metabolism of Sulfamethoxazole can be decreased when combined with Sorafenib.
SotalolSulfamethoxazole may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Sulfamethoxazole can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Sulfamethoxazole.
StiripentolThe serum concentration of Sulfamethoxazole can be increased when it is combined with Stiripentol.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Sulfamethoxazole.
SulodexideSulodexide may increase the hypoglycemic activities of Sulfamethoxazole.
SunitinibSulfamethoxazole may increase the hypoglycemic activities of Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Sulfamethoxazole.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sulfamethoxazole.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sulfamethoxazole.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Sulfamethoxazole.
TelaprevirThe metabolism of Sulfamethoxazole can be decreased when combined with Telaprevir.
TelavancinSulfamethoxazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinSulfamethoxazole may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Sulfamethoxazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Sulfamethoxazole.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sulfamethoxazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Sulfamethoxazole.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sulfamethoxazole.
TestosteroneTestosterone may increase the hypoglycemic activities of Sulfamethoxazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sulfamethoxazole.
TetrabenazineSulfamethoxazole may increase the QTc-prolonging activities of Tetrabenazine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sulfamethoxazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sulfamethoxazole.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sulfamethoxazole.
ThioridazineSulfamethoxazole may increase the QTc-prolonging activities of Thioridazine.
TicagrelorThe metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Sulfamethoxazole can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Tocilizumab.
TolazamideSulfamethoxazole may increase the hypoglycemic activities of Tolazamide.
TolbutamideSulfamethoxazole may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Sulfamethoxazole.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sulfamethoxazole.
TorasemideThe metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.
ToremifeneSulfamethoxazole may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sulfamethoxazole.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfamethoxazole.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.
TrazodoneTrazodone may increase the hypoglycemic activities of Sulfamethoxazole.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Sulfamethoxazole.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sulfamethoxazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sulfamethoxazole.
TrimethoprimThe metabolism of Sulfamethoxazole can be decreased when combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sulfamethoxazole.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Sulfamethoxazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sulfamethoxazole.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sulfamethoxazole.
Valproic AcidThe metabolism of Sulfamethoxazole can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Sulfamethoxazole can be decreased when combined with Valsartan.
VandetanibSulfamethoxazole may increase the QTc-prolonging activities of Vandetanib.
VemurafenibSulfamethoxazole may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Sulfamethoxazole can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sulfamethoxazole.
VilazodoneVilazodone may increase the hypoglycemic activities of Sulfamethoxazole.
VildagliptinVildagliptin may increase the hypoglycemic activities of Sulfamethoxazole.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sulfamethoxazole.
VogliboseVoglibose may increase the hypoglycemic activities of Sulfamethoxazole.
VoriconazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the hypoglycemic activities of Sulfamethoxazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sulfamethoxazole.
WarfarinThe metabolism of Warfarin can be decreased when combined with Sulfamethoxazole.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Sulfamethoxazole.
ZafirlukastThe metabolism of Sulfamethoxazole can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sulfamethoxazole.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sulfamethoxazole.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sulfamethoxazole.
ZileutonThe metabolism of Zileuton can be decreased when combined with Sulfamethoxazole.
ZimelidineZimelidine may increase the hypoglycemic activities of Sulfamethoxazole.
ZiprasidoneThe metabolism of Sulfamethoxazole can be decreased when combined with Ziprasidone.
ZiprasidoneSulfamethoxazole may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sulfamethoxazole.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Sulfamethoxazole.
ZuclopenthixolSulfamethoxazole may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
Gene Name:
folP
Uniprot ID:
P0AC13
Molecular Weight:
30614.855 Da
References
  1. Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. [PubMed:7486915 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Tetrahydrofolylpolyglutamate synthase activity
Specific Function:
Conversion of folates to polyglutamate derivatives.
Gene Name:
folC
Uniprot ID:
P08192
Molecular Weight:
45405.225 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, Watkins WM: In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52. [PubMed:7786001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos. 1995 Mar;23(3):406-14. [PubMed:7628308 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Arylamine n-acetyltransferase activity
Specific Function:
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
Gene Name:
NAT1
Uniprot ID:
P18440
Molecular Weight:
33898.445 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Arylamine n-acetyltransferase activity
Specific Function:
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
Gene Name:
NAT2
Uniprot ID:
P11245
Molecular Weight:
33542.235 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology. 1976;14(5):464-72. [PubMed:1031216 ]
  2. Angelakou A, Valsami G, Koupparis M, Macheras P: Use of 1-anilino-8-napthalenesulphonate as an ion probe for the potentiometric study of the binding of sulphonamides to bovine serum albumin and plasma. J Pharm Pharmacol. 1993 May;45(5):434-8. [PubMed:8099962 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23